Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …

Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

These guidelines update previous guidance published in 2005. They have been revised by
a group who are members of the UK and Ireland Neuroendocrine Tumour Society with …

Background The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against
pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. Methods …

Abstract We analyze SU (2)× U (1) theories, denoted by (n, m), in which there are n
neutrinos belonging to isodoublets and m neutrino isosinglets. The charged-current weak …

Background There is no established standard chemotherapy for patients with locally
advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 …

Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in …

Context Adjuvant fluorouracil has been shown to be of benefit for patients with resected
pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease …

Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …